Actively Recruiting
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-05-13
62
Participants Needed
7
Research Sites
304 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
T
Tesaro, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
CONDITIONS
Official Title
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Female gender
- ECOG performance status of 0-1
- Diagnosed with endometrial cancer of any histology
- Tumor shows mismatch repair deficiency (MMR-D), microsatellite instability-high (MSI-H), or POLE mutation
- Complete surgical staging with stage III or IVA disease
- Surgery performed between 3 and 12 weeks before starting therapy and patient has recovered from surgery
- Negative pregnancy test within 7 days before starting treatment if of childbearing potential
- Agrees to use adequate contraception from screening through 150 days after last treatment dose or is of nonchildbearing potential
- Will not breastfeed during the study and for 150 days after last treatment dose
- Adequate organ function as demonstrated by specific lab values within 14 days before treatment
You will not qualify if you...
- Prior chemotherapy, targeted therapy, or investigational therapy for endometrial cancer
- Previous treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 agents for endometrial cancer
- Unfit for radiation therapy due to recent or prior radiation, bone marrow radiation exposure, or history of pelvic radiation
- History or current diagnosis of vesicovaginal, enterovaginal, or colovaginal fistula
- Blood disorders contraindicating radiation
- Allergy or hypersensitivity to Dostarlimab or its components
- Immunodeficiency or recent systemic immunosuppressive therapy within 7 days prior to treatment
- Active tuberculosis or active pneumonitis
- History of interstitial lung disease
- Active infection requiring intravenous antibiotics
- Medical or psychiatric conditions interfering with study participation
- Prior bone marrow or solid organ transplantation
- Active or recent autoimmune or inflammatory disorders requiring immunosuppressive treatment within 3 years, with some exceptions
- Recent live vaccine within 30 days before study therapy
- Unwillingness or inability to consent or comply with the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge (All Protocol Activites)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Commack (All Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (All Protocol Activities)
Rockville Centre, New York, United States, 11570
Actively Recruiting
Research Team
Y
Ying Liu, MD, MPH
CONTACT
R
Roisin O'Cearbhaill, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here